PDS Biotechnology Corp. PDSB 深 沪
等待开盘 05-13 09:30:00 美东时间
1.10
-0.200
-15.38%
华盛通- 最 高1.30
- 今 开1.29
- 成交量 180.15万股
- 最 低 1.05
- 昨 收 1.30
- 总市值 6139.72万
- 52周最高 1.915
- 市盈率 静 --
- 换手率 3.23%
- 52周最低 0.5068
- 委 比 -39.07%
- 总股本 5581.57万
- 历史最高 17.85
- 量 比 2.39
- 振 幅 19.23%
- 历史最低 0.5068
- 每 手 1
- 风险率 0.28%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 大行互评！花旗银行、贝莱德获多家大行上调目标价；哈里伯顿、强生、Patterson获多家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持Knightscope"买入"评级，目标价从25美元升至26美元；杰富瑞：维持Allogene疗法"买入"评级，目标价从6美元升至10美元
04-16 10:14
Why Is PDS Biotechnology Stock Gaining Wednesday?
PDS Biotechnology says Phase 2 data show higher response rates and survival trends in colorectal cancer and prostate cancer studies.
04-16 01:14
PDS Biotechnology Announces Publication Of Clinical And Immunological Biomarker Data From Stage 1 Of Phase 2 Trial Evaluating Its Tumor-Targeted IL-12 Immunocytokine, PDS01ADC, In March 10 Issue Of JCO Oncology Advances
78% Objective Response Rate (ORR) with PDS01ADC; Parallel trial without PDS01ADC had 35% ORR 2-year survival rate of >80%; Parallel trial without PDS01ADC resulted in 2-year survival rate of ~35%Trials performed in
04-15 21:04
PDS Biotechnology Q4 EPS $(0.14) Beats $(0.20) Estimate
PDS Biotechnology (NASDAQ:PDSB) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.20) by 30 percent. This is a 33.33 percent increase over losses of $(0.21) per share from
03-30 21:41
PDS Biotechnology Reports Early Positive Results In Cancer Study, Tweaks Late-Stage Cancer Trial To Speed Up Potential Approval
PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today provided a business and
03-30 19:23
Earnings Scheduled For March 30, 2026
Companies Reporting Before The Bell • Liberty All Star Equity (NYSE:USA) is est...
03-30 19:11
PDS Biotechnology Corp Reported FY25 EPS Loss Of $0.74/Share, Cash Balance Of $26.7M
Full Year 2025 Financial ResultsNet loss for the year ended December 31, 2025, was approximately $34.5 million, or $0.74 per basic and diluted share, compared to a net loss of $37.6 million, or $1.03 per basic and
03-30 19:08
PDS Biotechnology Receives Nasdaq Noncompliance Notice, Gets Time Through Aug. 24 To Regain Compliance
https://www.sec.gov/ix?doc=/Archives/edgar/data/1472091/000114036126007478/ef20067044_8k.htm#fact-identifier-5
03-04 01:04
PDS Biotechnology Adopts Amended Protocol To Its Phase 3 VERSATILE-003 Clinical Study
PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced the adoption of a
02-20 21:36
PDS Biotechnology Announces U.S. Patent Office Issues Notice Of Allowance For Its PDS0101 Asset
PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the U.S.
01-22 21:46
